{"paper_id":"710071b1-c508-49b2-8088-57eaf67c8e2f","body_text":"In 1999, Dr Susan Treloar, Professor Nick Martin and colleagues published their landmark twin study reporting the first estimate for the heritability of endometriosis ( Treloar  et al. , 1999 ). Their estimate of 51% was an important result, leading several groups to begin mapping the genetic factors contributing to increased endometriosis risk. Gene mapping efforts gained momentum as methods for low-cost genotyping and gene regulation studies improved with advances in technology and computing power. In 2008, the International Endometriosis Genetics Consortium (IEGC) was formed to combine multiple datasets, increase power for discovery and speed up progress ( Painter  et al. , 2011 ;  Rahmioglu  et al. , 2015 ;  Montgomery, 2020b ). The most recent IEGC study ( Rahmioglu  et al. , 2023 ) reported 42 genomic regions significantly associated with endometriosis risk.\nSuccess in follow-up and translation of discoveries from the genetic studies has been mixed. The small effect sizes of individual risk loci and difficulty in translating mapped variation in common complex diseases to functional pathways have slowed progress. Although limited in scope, follow-up studies have identified target genes influencing disease biology ( Mortlock  et al. , 2020 ,  2023 ;  Rahmioglu  et al. , 2023 ) and begun to identify novel drug targets ( Tapmeier  et al. , 2021 ). At the same time, analyzing large publicly available datasets including the UK Biobank, FinnGen, and extensive results from large genetics consortia provides new opportunities to answer important questions about comorbid conditions associated with endometriosis and their implications for clinical practice ( McGrath  et al. , 2023c ;  Petraglia  et al. , 2026 ).\nDespite this progress, results from genetic studies are not widely applied in much of the research on disease causation, heterogeneity and clinical trials. Some commentators have questioned the value of genetic studies because known genetic risk factors explain such a small fraction of disease variance (Endometriosis Initiative, 2024) or lack mechanistic links between risk variants and disease pathophysiology ( Marquardt  et al. , 2023 ). The aims of this review are to summarize the last 25 years of genetic studies in endometriosis and address these important issues, including the proportion of disease variance explained by genetic risk factors, the challenges in establishing direct links between genetic associations and disease pathophysiology, and current understanding of the genetic architecture underlying endometriosis and its common comorbid conditions. In addition, this review seeks to highlight future directions to better integrate genetic studies with cell-based models, functional studies, and clinical research to generate deeper biological insights and improve clinical outcomes.\n\nA comprehensive review of the scientific literature on the genetics of endometriosis was undertaken using systematic searches of the MEDLINE (PubMed) database hosted by the National Center for Biotechnology Information and Google Scholar, covering publications available up to June 2026. Peer-reviewed research articles and reviews were identified using the search terms “endometriosis AND (genetics OR GWAS OR genetic risk factors)”. For studies addressing the functional characterization of genetic risk loci, additional searches employed the terms “endometriosis AND (genotype–phenotype associations OR colocalization OR eQTL OR mQTL OR multi omics methods)”. To identify studies examining shared genetic risk between endometriosis and comorbid conditions, the search strategy included “endometriosis AND (genetic correlation OR colocalization OR Mendelian randomisation)”.\nPrimary search results were supplemented by targeted searches for publications addressing the genetic architecture of complex diseases, as well as manual screening of reference lists from key review articles and original research papers. Inclusion was mainly restricted to primary peer-reviewed research articles published in English. Selected review articles were also included where they provided important conceptual insights or synthesized substantial bodies of earlier work with limited direct relevance to the current discussion, such as early candidate gene studies. Publications reporting discoveries related to genetic risk factors for endometriosis and studies interpreting their biological and clinical significance were critically evaluated and discussed.\n\nEvidence for a genetic influence on endometriosis risk had been accumulating prior to the landmark study by  Treloar  et al.  (1999) . There is an increased incidence of endometriosis among first-degree relatives of affected individuals in both hospital and population samples, although many of these studies were limited by sample size and potential ascertainment bias ( Ranney, 1971 ;  Simpson  et al. , 1980 ;  Lamb  et al. , 1986 ;  Coxhead and Thomas, 1993 ;  Moen and Magnus, 1993 ;  Kennedy  et al. , 1995 ). To quantify the genetic contribution to endometriosis risk, Treloar and colleagues conducted a twin study comparing disease concordance between monozygotic (MZ) and dizygotic (DZ) twins. Their analysis of Australian twin data revealed a significantly higher concordance rate among MZ twins, with a heritability estimate of 51%. A subsequent study in Sweden yielded a comparable heritability estimate of 47% ( Saha  et al. , 2015 ). Both estimates suggest that genetic factors account for approximately half of the variation in endometriosis risk. These estimates of heritability are similar to those reported for other reproductive traits, including age at menarche, age at menopause, and uterine fibroids ( McGrath  et al. , 2021 ), supporting a substantial genetic component to reproductive health.\n\nEarly mapping studies employed two main strategies: linkage analysis, which had proven effective in identifying mutations for rare diseases ( Treloar  et al. , 2005 ), and candidate gene studies ( Montgomery  et al. , 2008 ;  Rahmioglu  et al. , 2015 ). Both approaches were feasible given the genetic marker technologies available at the time but ultimately had limited success. While linkage studies successfully mapped loci underlying monogenic disorders, they mostly failed when applied to common diseases because the individual causal variants typically exerted small effects, making them difficult to detect through co-segregation in pedigrees ( Sidorenko  et al. , 2024 ). Candidate gene studies also failed in part due to the small effect sizes of individual variants. Few reported candidate gene associations with endometriosis or any complex diseases replicated in larger, more robust genome-wide association studies (GWAS) ( Duncan  et al. , 2019 ;  Montgomery, 2020a ). Most studies relied on small sample sizes and failed to adequately correct for multiple testing, which undermined the reliability of their findings. Applying more stringent multiple testing corrections, equivalent to those used in GWAS, would have reduced false positive results ( Montgomery, 2020a ).\nLinkage studies in endometriosis identified two genomic regions possibly associated with endometriosis. A region on chromosome 10q26 showed evidence of linkage ( Treloar  et al. , 2005 ) but subsequent extensive fine mapping across this region did not support the association ( Painter  et al. , 2011 ). Linkage analyses conducted in families with three or more endometriosis cases identified a high-penetrance susceptibility locus for endometriosis on chromosome 7p ( Zondervan  et al. , 2007 ).\nGenetic and functional follow-up identified the neuropeptide S receptor 1 ( NPSR1 ) gene and the encoded protein Neuropeptide S (NPS) as a potential nonhormonal target for the treatment of endometriosis ( Tapmeier  et al. , 2021 ). Follow-up studies suggest NPS may induce cell invasion and actin cytoskeleton remodelling ( Prisinzano  et al. , 2024 ) and support a role for  NPSR1  antagonists in blocking peripheral inflammation ( Berger  et al. , 2025 ).\nThe first strong evidence for genetic risk factors associated with endometriosis was reported in a Japanese study ( Uno  et al. , 2010 ). This was followed by a series of GWAS conducted in different populations, including European ( Painter  et al. , 2011 ), USA ( Albertsen  et al. , 2013 ), Icelandic ( Steinthorsdottir  et al. , 2016 ), Polish ( Sobalska-Kwapis  et al. , 2017 ), and Taiwanese ( Sheu  et al. , 2024 ) cohorts. To enhance statistical power and identify robust associations, meta-analyses combining data from multiple populations have been conducted ( Nyholt  et al. , 2012 ;  Rahmioglu  et al. , 2012 ,  2023 ;  Sapkota  et al. , 2017 ;  Koller  et al. , 2026 ).\nA meta-analysis of data from 60 674 cases and 701 926 controls of European and East Asian descent identified genome-wide significant association with 42 genomic regions ( Rahmioglu  et al. , 2023 ), of which 31 regions were novel. The study replicated 11 of 15 regions previously associated with endometriosis ( Uno  et al. , 2010 ;  Painter  et al. , 2011 ;  Nyholt  et al. , 2012 ;  Albertsen  et al. , 2013 ;  Sapkota  et al. , 2015a ,  b ,  2017 ;  Steinthorsdottir  et al. , 2016 ). Additional genetic risk factors continue to be identified with increasing sample size. The most recent meta-analysis analyzed data from ∼1.4 million women, including 105 869 cases from diverse ancestries ( Koller  et al. , 2026 ). This cross-ancestry analysis identified genome-wide significant association for 80 independent variants, including 37 novel results ( Koller  et al. , 2026 ). Some differences in significant results between published studies are likely due to case ascertainment. Genetic association with  IL1A  (Chr 2p13) and  FN1  (Chr 2q35) regions was not replicated in the recent International Endometriosis Genetics Consortium (IEGC) study ( Rahmioglu  et al. , 2023 ). This was attributed to heterogeneity in case ascertainment across studies with a higher proportion of less severe cases in the IEGC study ( Rahmioglu  et al. , 2023 ). Effect sizes for the risk variants in the  IL1A  and  FN1  regions are higher for severe disease, consistent with previous results ( Sapkota  et al. , 2017 ). Both these regions again showed genome-wide significant association in the most recent meta-analysis ( Koller  et al. , 2026 ).\nThe association of rs10965235 on chromosome 9p21, initially reported in the Japanese population ( Uno  et al. , 2010 ), appears to be population specific since rs10965235 is not polymorphic in European populations ( Painter  et al. , 2011 ). Associations with the  RND3-RBM43  region at chromosome 2q23.3 ( Albertsen  et al. , 2013 ) and  TTC39B  at chromosome 9p22 ( Steinthorsdottir  et al. , 2016 ) reported in earlier studies were not replicated in subsequent meta-analyses ( Sapkota  et al. , 2017 ;  Rahmioglu  et al. , 2023 ) also suggesting potential population differences, although association in the  TTC39B  region identified in the Icelandic population did replicate in samples from the Danish National Birth Cohort ( Steinthorsdottir  et al. , 2016 ). A recent GWAS in the Taiwanese population identified two novel loci, C5orf66/C5orf66-AS2 (5q31.1) and the  STN1  (STN1 Subunit of CST Complex, 10q24.33) not previously reported in European studies ( Rahmioglu  et al. , 2023 ). Although cross-ancestry analysis increased the discovery of genome-wide associations in the most recent analysis, no ancestry specific variants were identified across population groups ( Koller  et al. , 2026 ). However, heterogenous effects across populations were reported for six regions ( WNT4 ,  GREB1 ,  KDR ,  SYNE1 ,  FSHB , and  VEZT ) ( Koller  et al. , 2026 ).\nThe genetic architecture for a disease or trait depends on how many genetic variants are involved, how common they are, and how much they affect the trait. Studies using GWAS have shown that genetic risk for most common diseases, including endometriosis, results from the additive effects of many variants each with small effects ( Visscher  et al. , 2021 ;  Rahmioglu  et al. , 2023 ). There is little evidence yet that single gene mutations with large effects play a role in endometriosis ( Sapkota  et al. , 2017 ). As seen for other diseases ( Agrawal  et al. , 2025 ), many additional common risk variants will be discovered in future studies with larger samples.\nGenetic studies remain heavily biased towards European populations owing to historical data availability, and findings do not always generalize well to other ancestries. The recent cross-ancestry analyses demonstrates heterogeneity in effect sizes, highlighting both shared biology and potential ancestry-specific genetic effects ( Koller  et al. , 2026 ). In addition, extending studies into non-European ancestries with detailed genetic and phenotypic data and in diverse countries with different healthcare systems may provide unique information about the various environmental factors that affect disease risk and their relation to genetic risk factors ( Peterson  et al. , 2019 ). It is expected this will be an active area of research for endometriosis in the future ( Gajbhiye  et al. , 2021 ;  Bhurke  et al. , 2022 ).\nThe IEGC meta-analysis found 42 regions in the genome linked to endometriosis ( Rahmioglu  et al. , 2023 ). The strongest genetic variants or lead single nucleotide polymorphisms (SNPs) from each region explained only 1.62% of the overall variation in symptoms, or about 3% of the genetic risk, assuming the heritability is 50% ( Rahmioglu  et al. , 2023 ). There are secondary independent signals in several regions, and when all 49 independent lead SNPs are included, the variance explained increased slightly to 1.98% of phenotypic variance and ∼4% of genetic risk ( Rahmioglu  et al. , 2023 ).\nAs noted by others ( Marquardt  et al. , 2023 ; Endometriosis Initiative, 2024), the genome-wide significant lead SNPs explain only a small proportion of the variance in endometriosis risk. However, when looking at all common SNPs across the genome, we get a different picture. This broader estimate, called SNP heritability, includes the small contributions to endometriosis risk from many SNPs across the genome, not just the small number of genome-wide significant SNPs from our current GWAS of modest size. The SNP heritability for endometriosis explained 27% of disease risk in the first European GWAS ( Painter  et al. , 2011 ) and has stayed fairly consistent in later studies ( Lee  et al. , 2013 ,  2017 ). Common SNPs together explain about 53% of the genetic risk estimated from twin studies, and 26% of the overall variation in endometriosis.\nThese genetic estimates are based on treating all endometriosis cases as one group. However, endometriosis is a heterogeneous disease with highly variable clinical presentation. A key question is whether it is a single disease with variable symptoms or has distinct subtypes. The disease has many observable heterogenous features and patients experience variable symptoms; severe menstrual pain, subfertility or both, and a range of co-occurring conditions that significantly impact quality of life ( Horne and Missmer, 2022 ;  As-Sanie  et al. , 2025 ). Endometriosis in the pelvis can be classified as ‘superficial’ (<5 mm penetration), ‘deep’ (>5 mm penetration), or ovarian (cysts on the ovaries), may be associated with pelvic adhesions, and extra-pelvic endometriosis has been reported in some cases ( Giudice, 2010 ;  Horne and Missmer, 2022 ). Surgical excision/ablation of the lesions is sufficient to relieve symptoms in some, but not others.\nDisease subtypes could relate to the physiological, symptomatic, or molecular features of the endometriosis lesions. Important evidence from genetic studies supporting different disease subtypes is that genetic risk is higher in more severe cases. For example, in cases classified as Stage III/IV by the American Fertility Society (AFS), the SNP heritability was 0.34, twice the estimate of 0.15 seen in milder Stage I/II cases ( Painter  et al. , 2011 ). This increased genetic risk associated with more severe disease is not uniform. Effect size estimates for some lead SNPs show much greater effects in severe (AFS Stage III/IV) cases compared with all cases, with a trend for SNPs with larger effect sizes to show the biggest differences.\nGenetic differences in disease severity, as defined by AFS scores, have been investigated using available datasets that integrate both genotype data and AFS classifications. However, the AFS classification has limitations, and there is a growing shift towards alternative frameworks that better capture the heterogeneity of endometriosis phenotypes. For example, the most recent GWAS meta-analysis identified five regions that were genome-wide significant only in clinically defined endometriosis cases ( GRB14  on chr2,  CABS1  on chr 4,  RNA5SP375  on chr 12,  RP11-467I17.1  on chr 16, and  ZHX3  on chr 16) and one region ( LINC00485  on chr 12) only significant in self-reported cases suggesting phenotypic definitions of endometriosis influence the specificity of gene discovery ( Koller  et al. , 2026 ). Increasing the availability of datasets with detailed phenotype and genetic data will facilitate future studies to understand the genetic architecture of specific disease subtypes and the heterogeneity of endometriosis.\nThere is increasing interest in using genetic variants associated with a condition for patient stratification or risk prediction in clinical settings. This risk can be represented as a score, termed a genetic risk score (GRS) or polygenic risk score (PRS). In its simplest form, a GRS is calculated as the sum of the effects for the risk-increasing alleles for an individual, in some cases weighted by the effect of each allele estimated in GWAS. Improving the clinical risk assessment of endometriosis is important as the symptoms of endometriosis can be non-specific, there is a long diagnostic delay, and the definitive diagnosis of laparoscopic surgery is invasive.\nKloeve-Mogensen  et al.  (2021)  evaluated the utility of a 14-SNP genetic risk score (GRS) for endometriosis in a combined Danish cohort (389 cases, 664 controls) and the UK Biobank (2967 cases, 256 222 controls). The GRS was significantly associated with endometriosis diagnosis, yielding an AUC of 0.64 in the Danish cohort. Individuals in the top 10% of the GRS distribution had a threefold increased risk compared to those with average scores. Notably, ovarian endometriosis exhibited the highest AUC in both cohorts, suggesting either a greater genetic burden or better predictive performance of the GRS for this subtype. Conversely, the GRS showed poor predictive value for adenomyosis, supporting the notion that these are genetically distinct conditions.\nIn a more recent analysis,  McGrath  et al.  (2025)  derived a GRS from summary statistics of 28 382 independent endometriosis cases. Applying this in the UK Biobank, the mean GRS was higher in cases compared to controls, with an AUC of 0.61. Compared to individuals at the 50th percentile, those in the 1st centile had an odds ratio (OR) of 0.38, while those in the 100th centile had an OR of 3.67. In the recent cross-ancestry study ( Koller  et al. , 2026 ), individuals of European ancestry in the highest GRS quartile had an increased odds of endometriosis (OR = 2.19, 95% CI = 2.07–2.32) compared with individuals in the lowest quartile. GRS demonstrated cross-ancestry transferability but with reduced predictive performance across populations reflecting the genetic distance between European and the other population groups ( Koller  et al. , 2026 ), emphasizing the need for more diverse datasets.\nAs noted earlier, evidence supports variation in genetic architecture by disease stage with a higher proportion of variance explained by the GRS for severe disease ( Painter  et al. , 2011 ;  Rahmioglu  et al. , 2023 ). The ability to predict disease using genetic risk factors is strongest for severe (Stage IV) cases, but the GRS for mild cases does provide some prediction across samples ( Sapkota  et al. , 2015a ). GRS estimates show high technical reproducibility using established genotyping platforms and quality control pipelines ( Lin  et al. , 2026 ) but prediction accuracy is limited for most common diseases ( Zeng and Visscher, 2025 ). For endometriosis, the current AUC of 0.61 limits clinical utility ( McGrath  et al. , 2025 ;  Koller  et al. , 2026 ). It may be useful for risk stratification when combined with clinical features or other risk factors. In future, predictive power may also increase from larger GWAS datasets, stratification by subtypes, inclusion of rare variants, and enhanced statistical methodologies incorporating functional evidence into the risk estimates ( Zeng and Visscher, 2025 ;  Wainschtein  et al. , 2026 ).\nIdentifying coding variants that increase risk of endometriosis and modify protein function through amino acid substitutions, altered stop signals, or variable splicing is a direct approach to discover functionally significant risk genes. While imputation methods have improved genome coverage for common variants in coding regions, they have limitations in detecting rare variants. This is because the accuracy of single-variant tagging declines markedly for variants with minor allele frequencies (MAFs) less than 5%.\nIn an early study, coding variants from an Illumina exome-array were genotyped directly in 7164 cases and 21 005 controls of European ancestry to evaluate the role of protein-modifying variants ( Sapkota  et al. , 2017 ). After quality control, single-variant analysis included 23 755 rare variants (MAF < 1%) and 8858 low-frequency variants (1%<MAF < 5%). This approach was not fruitful: one low-frequency variant (rs1801232) reached statistical significance in the discovery set following correction for multiple testing but failed replication in an independent sample, indicating much larger cohorts and improved rare variant typing will be necessary.\nPotential high-risk variants have been reported from exome sequencing in two families each with four affected individuals, and in an endometriosis case study ( Peng  et al. , 2021 ;  Nousiainen  et al. , 2023 ;  Santin  et al. , 2023 ;  Kina  et al. , 2024 ). In one family from Finland ( Nousiainen  et al. , 2023 ), rare segregating variants that might predispose to endometriosis were reported in  FGFR4  (Fibroblast Growth Factor Receptor 4),  NALCN  (Sodium Leak Channel, Non-Selective), and  NAV2  (Neuron Navigator 2). Rare variants in two different genes,  TNFRSF1B  (TNF Receptor Superfamily Member 1B) and  GEN1  (GEN1 Holliday Junction 5' Flap Endonuclease) were reported in a second family from Türkiye ( Kina  et al. , 2024 ). Sequencing studies in two small cohorts identified five rare protein-coding variants and two novel mutations in  DYSF  (Dysferlin) in a Chinese population ( Peng  et al. , 2021 ) and several rare variants or private mutations in endometriosis cases from Italy ( Santin  et al. , 2023 ). Validation of a role for any of these variants in endometriosis will require functional studies or possible replication in independent samples.\nWhile whole-genome sequencing (WGS) remains expensive for the large-scale studies required to reliably identify rare variants associated with disease, data for endometriosis cases are becoming available through resources such as the UK Biobank, OurFutureHealth ( Cook  et al. , 2025 ) and AllofUS ( Kumar  et al. , 2025 ). This will enable a more comprehensive evaluation of rare variants for endometriosis. Recent analysis of WGS data in the UK Biobank helped to quantify the contributions of both rare and common variants for 34 complex traits (not including endometriosis) ( Wainschtein  et al. , 2026 ). WGS captured approximately 88% of the estimated heritability for these traits, with 20% attributed to rare variants and 68% to common variants. The study provides a good estimate of the contribution of rare variants to genetic variation and demonstrates that the heritability for some traits can be fully accounted for by the observed variants from WGS ( Wainschtein  et al. , 2026 ).\nAnother relevant source of DNA variation is somatic mutations. They arise in individual cells from errors in DNA replication or exposure to exogenous mutagens ( Forsberg  et al. , 2017 ). Somatic mutations are not inherited but represent important genomic alterations that may interact with germline variation to influence gene regulation and cellular fate. Their frequency is a function of the number of cell divisions since conception and the mutation rate per division ( Forsberg  et al. , 2017 ). High rates of proliferation occur in the endometrium, a key disease-relevant tissue in endometriosis. In this tissue, the functionalis layer undergoes cyclical shedding and regeneration during each menstrual cycle and may be one source of cells that initiate lesions ( Ochoa Bernal and Fazleabas, 2024 ). The high rates of cellular turnover increase the likelihood of mutations occurring, and somatic mutations have been observed in both eutopic endometrium and in endometriotic lesions ( Anglesio  et al. , 2017 ;  Suda  et al. , 2018 ;  Lac  et al. , 2019 ;  Koppolu  et al. , 2021 ), with a predominance in epithelial cell populations.\nSomatic mutations are likely to be functionally relevant to disease pathogenesis. Mutations in known cancer driver genes occur more frequently than mutations in non-driver genes ( Anglesio  et al. , 2017 ;  Koppolu  et al. , 2021 ), and alterations in cancer driver genes may provide a selective advantage to cells with enhanced ability to survive, implant and proliferate. Accumulating evidence supporting their functional significance underscores the need to investigate the relationship between common germline variants and somatic mutational processes in endometriosis.\n\nA major challenge of genetic mapping in complex diseases lies in the fact that most lead SNPs identified by GWAS are located in non-coding regions of the genome. Most non-coding disease risk variants likely modify local regulation of a critical gene or genes (defined as risk genes for this review) to modify disease risk ( Mostafavi  et al. , 2023 ). There are usually multiple genes in the vicinity of each lead SNP and no easy way to identify the critical risk gene or genes. Multiple methods must be applied combining genetic and functional studies ( Qi  et al. , 2024 ). For a limited number of traits, a high proportion of GWAS ‘hits’ are situated near well-recognized candidate genes. Examples include age at menopause and dizygotic twinning ( Kentistou  et al. , 2024 ;  Montgomery, 2024 ), where regulatory pathways are well studied and critical genes have been clearly identified. Despite the numerous genetic markers associated with human traits and diseases, slow progress in defining causal genes and pathways continues to limit translation of GWAS discoveries. Endometriosis is no exception, but some insights are beginning to emerge.\nSome GWAS signals for endometriosis map close to strong candidate genes ( Fung  et al. , 2018 ;  GTEx Consortium, 2020 ;  Mortlock  et al. , 2020 ,  2023 ). Endometriosis is an oestrogen dependent disease and five independent signals for endometriosis are located in or near  ESR1  (Estrogen Receptor 1 gene) on chromosome 6 ( Rafnar  et al. , 2018 ;  Marla  et al. , 2021 ;  Rahmioglu  et al. , 2023 ;  Koller  et al. , 2026 ). These span the region from  CCDC170  (Coiled-Coil Domain Containing 170) immediately upstream of  ESR1  to  SYNE1  (Spectrin Repeat Containing Nuclear Envelope Protein 1) ( Sapkota  et al. , 2017 ;  Marla  et al. , 2021 ). Two high confidence variants within the introns of  SYNE1  and  ESR1  are strongly correlated with variants driving expression of  ESR1  and DNA methylation near  ESR1  and  SYNE1  ( Rahmioglu  et al. , 2023 ). Risk factors for breast cancer, age of menarche, age at first birth, and uterine fibroids also map to this region but the risk SNPs for endometriosis and other reproductive traits are largely distinct ( Rafnar  et al. , 2018 ;  Marla  et al. , 2021 ) suggesting complex regulation of these genes across tissues and cell types.\nAnother key candidate is  FSHB , which encodes the β subunit of follicle-stimulating hormone ( Sapkota  et al. , 2017 ;  Rahmioglu  et al. , 2023 ). The lead SNP (rs3858429) ( Rahmioglu  et al. , 2023 ) is highly correlated to variants upstream of  FSHB . The association signal in this region upstream of the  FSHB  promoter includes four highly correlated SNPs and the region exhibits open chromatin in gonadotrophs in the pituitary gland ( McGrath  et al. , 2021 ). These SNPs are associated with  in vivo  concentrations of FSH, luteinizing hormone (LH), steroid hormone binding globulin (SHBG), and testosterone (T) ( Mbarek  et al. , 2024 ) and likely act through effects on hormonal regulation. The common allele (frequency = 0.84) associated with increased FSH concentrations is also associated with multiple reproductive traits and diseases including increased endometriosis risk, shorter menstrual cycles, and increased dizygotic twinning frequency ( McGrath  et al. , 2021 ).\nInterestingly,  ARL14EP  (ADP Ribosylation Factor Like GTPase 14 Effector Protein), a gene that lies immediately downstream of  FSHB , is also implicated. It is expressed in many tissues including strong expression in immune calls, ovaries, testis, and uterus ( McGrath  et al. , 2021 ;  Rahmioglu  et al. , 2023 ;  Mbarek  et al. , 2024 ). The lead SNP for endometriosis (rs3858429) ( Rahmioglu  et al. , 2023 ) is highly correlated with a SNP in the 5′ UTR region regulating expression of  ARL14EP  where the common C allele is associated with lower  ARL14EP  expression in testis ( GTEx Consortium, 2020 ). The effector protein encoded by  ARL14EP  regulates immune responses via MHC class II export ( Paul  et al. , 2011 ) suggesting a possible link between hormone and immune regulation at this locus ( Rahmioglu  et al. , 2023 ).\nA common method of annotating GWAS risk variants is by integration with multi-omics datasets, which provide maps of the genetic regulation of gene expression (eQTLs), methylation (mQTLs), and more recently protein expression (pQTLs). Genetic variation has been shown to influence DNA methylation signals ( Min  et al. , 2021 ) and contribute to expression differences in a substantial proportion of genes ( GTEx Consortium, 2020 ;  Vosa  et al. , 2021 ). SNPs associated with variation in methylation or gene expression offer insights into potential risk genes, especially when observed in disease-relevant tissues. However, regulatory variants are widespread in the genome, so overlap in disease-associated SNPs and regulatory signals may be driven by linkage disequilibrium or chance ( Liu  et al. , 2019 ). Statistical methods can test the alternative models to assess the likelihood of shared causal variants ( Wallace  et al. , 2012 ;  Zhu  et al. , 2016 ).\nAnalysis of genetic effects on gene expression for risk regions in the IEGC meta-analysis was conducted in three datasets for endometrium and uterus, and one large dataset for blood ( Rahmioglu  et al. , 2023 ). Overlap with eQTL and mQTL datasets ( GTEx Consortium, 2020 ;  Mortlock  et al.  2020 ,  2023 ;  Min  et al. , 2021 ;  Rahmioglu  et al. , 2023 ) provides increasing evidence for GWAS risk variants regulating expression of risk genes and methylation signals ( Table 1 ). Risk regions often harbor multiple variants, and a single causal SNP can influence the expression of more than one gene, further complicating the identification of causal variants and their target genes. Four regions in the IEGC analysis ( Rahmioglu  et al. , 2023 ) exhibited multiple independent signals: three regions ( GREB1 /2p25.1,  CDKN2-BAS1 /9p21.3, and IGF1/12q23.2) had two signals each and  SYNE1 /6q25.1 had five independent signals ( Rahmioglu  et al. , 2023 ). Examples of genetic regulation of risk genes include variants in enhancers or promoters that alter gene expression of one or more candidates, variants modifying hormonal concentrations, or effects on transcript splicing ( Fig. 1 ).\nGenetic risk factors influence functional pathways through different mechanisms . Examples of different mechanisms for how lead single-nucleotide polymorphisms (SNPs) influence regulation of genes and hormonal concentrations: ( a ) the common alleles of correlated risk SNPs on chromosome 11 associated with increased risk of endometriosis are also associated with an increase in follicle-stimulating hormone (FSH) concentrations and decreased expression of ARF Like GTPase 14 Effector Protein ( ARL14EP) ; ( b ) on chromosome 1, risk SNPs show independent signals increase expression of the long non-coding RNA  LINC00339  and decrease expression of Cell Division Cycle 42 ( CDC42) ; ( c ) on chromosome 2, the risk SNP is associated with alternative splicing of transcripts for Growth Regulating Estrogen Receptor Binding 1 ( GREB1 ); and ( d ) the risk SNP on chromosome 12 lies in a bidirectional promoter decreasing expression of both FYVE, RhoGEF and PH Domain Containing 6 ( FGD6)  and Vezatin, Adherens Junctions Transmembrane Protein ( VEZT) . Created in BioRender. Montgomery, G. (2026).  https://BioRender.com/3m1rpt7 .\nEndometriosis risk regions from  Rahmioglu  et al.  (2023)  with evidence 1  that risk SNPs regulate expression of local genes through expression quantitative trait loci (eQTLs) or DNA methylation quantitative trait loci signals (mQTLs).\neQTLs and mQTLs with statistical support that the same genetic variant affects endometriosis risk and gene expression or methylation signals.\nData sets for gene expression or methylation in endometrium (EM) or blood.\nGene regulated by the functional single nucleotide polymorphism (SNP) (eQTLs) or nearest gene to modified methylation signals.\nLinkage disequilibrium (LD) between the lead and functional SNPs estimated as  r 2  or  D ′.\nOne example of complex effects is the lead SNP rs10917151 on chromosome 1p36 ( Rahmioglu  et al. , 2023 ) which is highly correlated with rs3820282 in the first intron of  WNT4  (Wnt Family Member 4). This region shows chromatin looping to the promoter of  LINC00339  ( Fig. 1 ) increasing the expression of this long non-coding RNA ( Powell  et al. , 2016 ). The risk allele (T) for rs3820282 generates a novel enhancer with strong binding for  ESR1  ( Zhang  et al. , 2017 ).  LINC00339  is now known to be transcribed into a protein, expressed in endometriosis lesions, and has effects on the expression of genes involved in immune defence pathways ( Holdsworth-Carson  et al. , 2021 ). Direct effects of rs3820282 on  WNT4  expression in human endometrium were not observed ( Powell  et al. , 2016 ;  Mortlock  et al. , 2020 ), yet evidence in mice suggests  WNT4  may be regulated by rs3820282: The DNA sequence around rs3820282 is 98% conserved in mice and gene editing to introduce the T risk allele at this site in mice resulted in upregulation of Wnt4 in endometrial stromal cells ( Pavlicev  et al. , 2024 ). The risk variant suppresses proliferation in the epithelium and enhances pro-implantation/invasion processes in the stroma. A second variant associated with endometriosis in this region lies in an intron of  CDC42 , interacts with the  CDC42  promoter and reduces expression of this gene ( Fig. 1 ) ( Powell  et al. , 2016 ). Knockdown experiments also suggest the  LINC00339  locus may regulate expression of  CDC42  ( Chen  et al. , 2018 ;  Pavlicev  et al. , 2024 ).\nThe likely causal gene at chromosome 2p25 is  GREB1 , an oestrogen-responsive gene involved in oestrogen receptor transcription, and cell proliferation in breast, prostate, and ovarian cancers ( Mortlock  et al. , 2019 ;  Rahmioglu  et al. , 2023 ). Analysis of RNA splicing shows a risk SNP strongly correlated with the lead GWAS SNP alters RNA splicing of  GREB1  in the ovary and endometrium ( Fig. 1 ) ( GTEx Consortium, 2020 ;  Yang  et al. , 2025 ).  GREB1  expression is upregulated by progesterone and GREB protein modifies downstream regulation of genes by progesterone influencing endometrial decidualization and embryo implantation ( Chadchan  et al. , 2024 ).  GREB1  is also regulated by oestrogen in both mouse and human endometriotic cells, affecting oestrogen-mediated gene expression. Differentially spliced transcripts may play a role in regulating these feed-forward loops for progesterone and oestrogen receptor in normal endometrial physiology and endometrial pathology.\nThe lead SNP on chromosome 7 alters expression of  TRA2A  (Transformer 2 Alpha Homolog).  TRA2A  encodes a protein with RNA recognition and plays a role in RNA splicing ( Rahmioglu  et al. , 2023 ). On chromosome 8, lead SNPs associated with endometriosis regulate methylations signals and the risk allele decreases expression of  GDAP1  (Ganglioside Induced Differentiation Associated Protein 1) ( Rahmioglu  et al. , 2023 ). This gene is also associated with severity of dysmenorrhea and neuronal development ( Barneo-Munoz  et al. , 2015 ;  Jones  et al. , 2016 ).\nAt chromosome 9p21, the risk SNP identified in a Japanese population ( Uno  et al. , 2010 ) affects expression of  CDKN2B-AS1 , a long-noncoding RNA overlapping the Cyclin Dependent Kinase Inhibitor  CDKN2B  ( Nakaoka  et al. , 2016 ). The lead SNP in this Japanese study is population specific and lies in a cis-regulatory element that interacts with the promoter of  CDKN2A-AS1  or  ANRIL , with allele specific expression of  ANRIL  in eutopic endometrial tissues and endometrial carcinoma cell lines ( Nakaoka  et al. , 2016 ).  ANRIL  regulates progression in the cell cycle including regulation of  CDKN2B  and modifies activity of multiple miRNAs involved in cellular processes including cell proliferation, invasion, and inflammation ( Sanchez  et al. , 2023 ). Dysregulation of  ANRIL  disrupts normal cell cycle control, leading to uncontrolled cell growth and  ANRIL  expression is upregulated in more than 20 types of cancer ( Sanchez  et al. , 2023 ). Subsequent GWAS studies in European populations identified an association between endometriosis and other variants at this region of chromosome 9p21 ( Sapkota  et al. , 2017 ;  Rahmioglu  et al. , 2023 ), but the functional role of these variants is yet to be determined.\nOn chromosome 12q22, the lead SNP lies in a bidirectional promoter with the risk allele increasing expression of both  FGD6  and  VEZT  in endometrium ( Fig. 1 ) ( Mortlock  et al. , 2022 ). Both VEZT and FGD6 have roles in cell adhesion and cytoskeletal remodelling relevant to the development of endometriotic lesions ( Guo  et al. , 2011 ; Holdsworth-Carson  et al. , 2016).  FGD6  is a member of a family of guanine nucleotide exchange factors regulating cellular development, plays a role in osteoclasts regulating the assembly of different actin-based protein networks, and activates another endometriosis candidate,  CDC42  ( Steenblock  et al. , 2014 ).  FGD6  is significantly overexpressed in gastric cancer samples, compared with adjacent normal tissues, and is associated with poor prognosis ( Zeng  et al. , 2021 ).  VEZT , an adherens junction transmembrane protein, is a putative tumour suppressor in gastric cancer and can inhibit growth, invasion and tumorigenesis ( Guo  et al. , 2011 ;  Miao  et al. , 2013 ).\nThe lead SNP on chromosome 15 regulates methylation signals and the risk allele decreases expression of the Signal Recognition Particle 14 gene ( SRP14 ) with additional evidence for chromatin interactions between regulatory regions for  SRP14  and the promoter of  BMF  (Bcl2 modifying factor) ( Rahmioglu  et al. , 2023 ). On chromosome 17, an associated risk SNP regulates expression of the  HOXB9  (Homeobox B9 HOX gene).  HOXB9  is a transcription factor influencing expression of genes related to organ development, tissue differentiation, and immune response ( Hjazi  et al. , 2024 ). The gene shows altered regulation in multiple malignancies, including increased expression in breast cancer associated with increased metastatic capacity and poor prognosis. Multi-omics analysis of the latest gene mapping results provides robust evidence for a role for  SEMA3F  in endometriosis pathogenesis and roles for  EEFSEC ,  UBE2D3 ,  DTD1 , and  VEZT  in cellular morphogenesis associated with endometriosis ( Koller  et al. , 2026 ).\nCommon genetic risk factors regulate epigenetic signals with roles in transcription and cellular programming. DNA methylation is the most widely studied epigenetic mark and can also be modified by exposure to environmental factors. Methylation signals in endometrial samples and their association with endometriosis were investigated in a large sample of 984 participants with genotype data ( Mortlock  et al. , 2023 ). Menstrual cycle phase was a major source of variation in methylation signals, suggesting cellular and hormonally driven changes across the cycle can regulate genes responsible for endometrial physiology and function. In this large study, no significant differences in the degree of methylation were detected for individual signals between all endometriosis cases and controls. Previously reported differences in methylation at candidate genes were not replicated, and this lack of replication may be due to use of eutopic versus ectopic tissue, small sample sizes used previously, and effects of variation across the menstrual cycle ( Mortlock  et al. , 2023 ). Four significant differences in DNA methylation signals were associated with severe (Stage III/IV) endometriosis, consistent with greater genetic effects on endometriosis risk in severe cases. Genes annotated to these differentially methylated sites include  EEF2  (eukaryotic translation elongation factor 2), which is downregulated in ectopic endometriosis lesions, and the nuclear transport receptor  TNPO2  (Transportin 2) highly expressed in the ovary, uterus, testis, and brain.\nAnalysis of genetic effects on methylation signals identified over 100 000 independent cis-mQTLs in endometrium, including 51 associated with risk of endometriosis ( Mortlock  et al. , 2023 ). Functional evidence for epigenetic targets contributing to endometriosis risk included methylation signals detected in predicted enhancers that interact with  GREB1  in the uterus and ovary. Two possible endometrial-specific mQTLs were also located in regulatory regions associated with the expression of endometriosis risk genes  LINC00339 ,  CDC42 , and  WNT4  on chromosome 1p36.12. As noted above, endometriosis-associated mQTLs on chromosomes 8, 15, and 17 are strongly correlated with SNPs associated with endometriosis in each region that alter transcription of  GDAP1 ,  SRP14 , and  HOXB9  ( Mortlock  et al. , 2023 ;  Rahmioglu  et al. , 2023 ).\nDevelopment of a methylation risk score aggregating effects across multiple DNA methylation sites and joint analyses with genetic risk factors ( Thong  et al. , 2025 ) demonstrated that the variance in endometriosis captured by both DNA methylation and common genetic variants combined (35%) was higher than estimates for either methylation (19.58%) and common genetic variants (28.83%) alone. The results suggest DNA methylation can influence endometriosis risk independent of genetic variation and further exploration in larger samples may shed light on how environmental exposures influence methylation and contribute to endometriosis risk ( Thong  et al. , 2025 ).\nTo date, there is functional support for only a limited set of genes regulated by genetic risk variants. In the absence of functional support, genes closest to the lead SNP can represent good proxies ( Mostafavi  et al. , 2023 ). Significant pathways from gene set enrichment analysis ( Mootha  et al. , 2003 ;  Subramanian  et al. , 2005 ) of genes implicated in endometriosis risk from the GWAS results and common somatic mutations include regulation of developmental processes involved in reproduction, reproductive system development, positive regulation of cell population proliferation, and epithelial cell differentiation ( Table 2 ). Results for protein–protein interactions between endometriosis risk genes in these pathways show key genes in each pathway are also connected through reported protein–protein interactions ( Fig. 2 ). The most recent GWAS results implicate pathways for cell differentiation, immune and hormonal regulation, tissue remodelling, and inflammation showing some overlap with previously reported pathways ( Koller  et al. , 2026 ). Many genes appear in multiple pathways, providing a mechanism where small genetic effects on regulation can be amplified by interactions within and between pathways. Thus, small genetic effects can have more profound effects on disease risk when several ‘hits’ are combined within common pathways.\nGene pathways implicated from genetic studies . Interactions between genes for three of the top 10 pathways identified in gene set analysis showing protein–protein interactions evaluated in the STRING database ( Szklarczyk  et al ., 2023 ) chosen from  Table 2 . The top 10 pathways included several related pathways and the pathways illustrated were chosen to show the top pathway GOBP_DEVELOPMENTAL_PROCESS _INVOLVED_IN_REPRODUCTION (Bonferroni adjusted  P -value 2.65E-06); the most significant pathway for cell proliferation GOBP_POSITIVE_REGULATION_OF_CELL_POPULATION_ PROLIFERATION (adjusted  P -value 4.06E-04); and GOBP_EPITHELIAL_CELL_DIFFERENTIATION (adjusted  P -value 1.01E-03) given the importance of epitheal cells in endometriosis lesion development. Purple lines connecting genes denote experimentally determined interactions, orange lines denote interactions derived from curated databases, and green lines denote interactions based on prediction and co-expression. Genes symbols in pink circles denote a target gene with evidence that risk SNPs regulate gene expression (expression quantitave trait loci, eQTL) or genes with frequenct somatic mutations associated with endometriosis. Created in BioRender. Montgomery, G. (2026).  https://BioRender.com/5wxetnd .\nThe top ten pathways for Gene Ontology Biological Processes (GOBP) from Human Gene Set Enrichment Analysis following Bonferroni adjustment for multiple testing.\nTotal number of genes in the set.\nNumber of genes from the set also implicational in endometriosis development.\nAdjusted  P -value for the Gene Set analysis following Bonferroni correction. A target gene list including genes supported by clear functional evidence, genes nearest to the top risk variants from GWAS studies ( Sapkota  et al. , 2017 ;  Rahmioglu  et al. , 2023 ) and the three most common genes with reported somatic mutations was submitted to the GENE2FUNC module of the Functional Mapping and Annotation of Genome-Wide Association (FUMA) software to evaluate expression patterns and shared molecular functions between the genes (Watanabe  et al. , 2017).\nGenetic studies on gene expression in endometrium have implicated some causal genes for endometriosis. However, the datasets available for endometriosis relevant tissues are based on small samples with limited statistical power for discovery ( Burrows  et al. , 2016 ;  Fung  et al. , 2018 ;  Mortlock  et al. , 2020 ). More generally, most GWAS ‘hits’ for complex diseases are not explained by known genetic effects on gene regulation ( Umans  et al. , 2021 ;  Mostafavi  et al. , 2023 ). Results from the GTEx Consortium suggest that only about 20% of GWAS hits colocalize with an eQTL in the GTEx dataset ( GTEx Consortium, 2020 ).\nThis gap in our understanding of how disease risk factors modify gene regulation may be explained in part through genetic effects that alter RNA splicing, or context-specific effects acting only during development or in specific cell types. However, contributions from these effects so far are also modest ( Mostafavi  et al. , 2023 ;  Yang  et al. , 2025 ). Attempts to understand this knowledge gap show genetic risk factors for complex diseases are enriched in regulatory elements that are under strong negative selection and show complex regulation across different tissues and cell types ( Mostafavi  et al. , 2023 ). In contrast, most reported genetic effects on gene expression are variants with relatively large effects, often observed in multiple tissues and not subject to the same negative selection. These observations suggest current eQTL studies lack power to discover the gene regulatory mechanisms modified by disease causing variants which are more likely to be specific to individual tissues or cell types ( Mostafavi  et al. , 2023 ). More powerful multi-omics datasets, including genetic effects on gene expression (eQTL), splice variation (sQTL), methylation (mQTL), and protein expression (pQTL) at the individual cell level, will be necessary to speed up detection of disease risk genes and mechanisms.\nDifferent methods are available to combine GWAS results with functional data to define risk genes. These different methods use distinct statistical frameworks and assumptions and results from the different methods are often inconsistent ( Liu  et al. , 2025 ). One approach to overcome these inconsistencies is to use a combination of the different methods to enable validation across different methods and window settings to improve accuracy and reproducibility ( Liu  et al. , 2025 ). Another limitation is that existing methods can integrate GWAS data with gene expression or epigenetic data but do not analyze multi-omics data simultaneously. Novel approaches to overcome this limitation include development of an integrated framework for joint analysis of GWAS and multi-omics QTL summary statistics ( Wu  et al. , 2023 ). Applying this framework to summary-level GWAS data for 50 complex traits showed that approximately 50% of GWAS signals are shared with at least one molecular phenotype. This framework is being extended to integrate GWAS and single-cell transcriptomic data to map trait-cell type associations ( Song  et al. , 2025 ). A recent study integrating large-scale endometriosis genetic risk data with single-cell transcriptomics, identified M2 macrophages as key drivers of disease susceptibility and implicated germline-regulated IL-1 signalling as a central, therapeutically actionable pathway underlying endometriosis pathogenesis and pain ( Ochoa  et al. , 2025 ). These findings motivate broader investigations that systematically extend GWAS and single-cell omic integration across cell types and disease stages to uncover additional causal cell types and pathways.\n\nThe observed size of the genetic effects on disease risk are not good predictors of the effects of targeting genetically validated causal genes and pathways for disease prevention or treatment. Genetic support for a biological pathway provides important evidence for causality, and thus a potential for therapeutic intervention. Yet, this does not imply that the biological pathway can only be targeted through the specific genetic risk factors.\nThere are good examples where the effect size for a genetic risk factor is small, but a potent population-wide therapy has been developed. The risk variant at the dopamine D2 receptor gene ( DRD2 ) locus with schizophrenia has a small genetic effect (risk ratio = 1.07). Despite this small genetic effect, dopamine D2 receptor antagonists can powerfully reduce schizophrenia symptoms revolutionizing care for individuals with schizophrenia, although incomplete efficacy and prominent side effects are acknowledged ( Duncan and Deisseroth, 2024 ). Similarly, with hot flushes, the risk allele for neurokinin B receptor gene ( TACR3 ) has a risk ratio of 1.12, but the highest dose of the neurokinin B receptor antagonist fezolinetant caused an 80.5% reduction in moderate/severe hot flushes after 4 weeks, and an 86.9% reduction in moderate/severe hot flushes after 12 weeks ( Duncan and Deisseroth, 2024 ).\nGenetic studies in endometriosis also demonstrate an important proof of concept of their value of defining critical pathways for future development of clinical treatments. Most drugs for primary medical management of endometriosis, including oral contraceptives, progestins and GnRH agonists target the reproductive endocrine system. Published GWAS studies ( Rahmioglu  et al. , 2023 ;  Koller  et al. , 2026 ) have identified multiple common genetic variants affecting endometriosis risk regulating genes within this system,  FSHB ,  ESR1 ,  GREB1 ,  BMPR2 , and a signal immediately downstream of  GNRH1  ( Fig. 3 ). In addition, the risk SNP on chromosome 1 introduces an ESR1 (oestrogen receptor 1) binding site modifying hormonal responses in carriers of the risk allele ( Zhang  et al. , 2017 ). Together, these results provide strong genetic support for this pathway. Of course, development of drugs targeting the pathway was based on prior functional evidence and not genetic validation of these targets. However, this example of multiple genetic effects influencing the key pathway targeted by most medical treatments in endometriosis suggests much greater focus on functional follow-up of other genetic risk genes will help to define causes of endometriosis and identify novel drug targets.\nGenes from the hypothalamic-pituitary-gonadal axis implicated from genome-wide association studies (GWAS) . Genes from the hypothalamic/pituitary hormone signalling pathways regulating female reproduction implicated from GWAS for endometriosis risk are shown with red labels. The genes are all supported by the results of the recent International Endometriosis Genetics Consortium analysis ( Rahmioglu  et al ., 2023 ). The figure was redrawn from a previously published figure that showed the hypothalamic-pituitary-ovarian axis with genes implicated in variation in twinning frequency and litter size ( Montgomery, 2024 ). Created in BioRender. Montgomery, G. (2026).  https://BioRender.com/1m3s7y9 .\n\nEndometriosis is increasingly considered as a multi-system disorder with multiple comorbidities ( Petraglia  et al. , 2026 ). Discoveries from GWAS of many thousands of SNPs associated with multiple traits and diseases enable novel analytical approaches to address important questions about disease subtypes, molecular mechanisms, comorbidity, and causality ( Visscher  et al. , 2021 ). Genetic studies offer advantages for comorbidity studies because variation for individuals is defined at conception and the effects of disease-associated germline variants are less influenced by the course of a disease. Genetic risk for an individual and a given disease can be calculated from GWAS results and genetic overlap between traits is estimated by genetic correlation. Another design now widely used to understand how modifiable risk factors influence disease risk is Mendelian Randomization (MR) ( Visscher  et al. , 2021 ). In MR studies, genetic variants associated with a related disease or risk factor of interest (identified through GWAS) are analyzed to assess their effects on the disease outcome. Where there is genetic overlap, direction of causation can be assessed. MR also offers a cost-effective approach to test hypotheses before more formal and expensive clinical trials or when direct studies are not possible ( Visscher  et al. , 2021 ). Details of relevant methods and applications for genetic correlation and MR studies in endometriosis have been reviewed recently ( McGrath  et al. , 2023c ), and these genetic approaches complement epidemiological studies, overcoming some issues of ascertainment bias.\nIndividuals diagnosed with endometriosis are at increased risk of developing many comorbid conditions ( Khan  et al. , 2025 ). Leveraging large genetic datasets, the GRS for endometriosis is correlated with multiple conditions (e.g. excessive and frequent menstruation, uterine fibroids, urinary incontinence and asthma), reproductive characteristics (earlier age at menopause, shorter menstrual cycle length, earlier age at menarche, earlier age at first live birth), multiple pain traits, psychiatric conditions, cancer, urinary, bone, cardiovascular conditions, and blood/urine biomarkers (e.g. lower testosterone, higher triglycerides, higher calcium) in females in the UKB ( McGrath  et al. , 2023c ). Some comorbidities can complicate diagnosis due to overlapping symptoms and can be affected by, or complicate, treatment plans ( Rahmioglu  et al. , 2023 ;  Yang  et al. , 2023 ;  Pujol Gualdo  et al. , 2025 ).\nThe genetic architecture of endometriosis and comorbidities can be leveraged to investigate whether a biological factor can explain each comorbid relationship. For traits genetically correlated with endometriosis, most correlations are moderate ( McGrath  et al. , 2023a , b ;  Rahmioglu  et al. , 2023 ;  Shigesi  et al. , 2025 ). There are exceptions. Clear cell carcinoma, a type of epithelial ovarian cancer, has a genetic correlation of 0.71 (where a genetic correlation of 1 would indicate an identical genetic architecture) ( Mortlock  et al. , 2022 ). The genetic correlation with pain-related traits beyond the pelvic region provides evidence of more complex relationships between endometriosis and pain ( Rahmioglu  et al. , 2023 ). We expect the number of traits genetically correlated with endometriosis to increase as more well-powered GWAS data are generated and as phenotypes are better defined to reduce heterogeneity. Nevertheless, the range of correlated conditions across multiple biological systems implies that a diverse set of biological processes contribute to endometriosis risk.\nThe co-occurrence of endometriosis with other conditions could imply causal relationships, shared biological pathways, or spurious correlations owing to a confounding factor. For example, endometriosis is reported to be causal for uterine fibroids, benign growths in the myometrium of the uterus ( Gallagher  et al. , 2019 ). Although the disease-relevant tissue differs, hormone-signaling pathways are shared, which suggest the significant MR result is explained by shared driving mechanisms ( Gallagher  et al. , 2019 ).\nFurther characterization of the comorbid relationships includes fine mapping of the risk SNPs and annotating shared target genes. Co-localization analysis can determine the likelihood that a given risk locus contains a variant that is causal for both traits. This approach identified rs6025, a missense variant in the Factor V gene ( F5 ), a variant identified as protective for endometriosis, diverticular disease, heavy menstrual bleeding and haemorrhoids ( McGrath  et al. , 2023a ). The mutation reduces the deactivation of Factor V protein, a coagulation cascade protein. This variant may influence retrograde menstruation, given the association with heavy menstrual bleeding, since menstrual volume is likely correlated with the occurrence and volume of retrograde menstrual fluid. Shared genetic risk factors and pathways identified between endometriosis, osteoarthritis, and rheumatoid arthritis implicate immune signalling, extracellular matrix organization, and inflammatory processes ( Shigesi  et al. , 2025 ).\nMalignant transformation of endometriosis to ovarian cancer was first suggested by  Sampson (1924) . MR approaches provide support for a causal effect of endometriosis on epithelial ovarian cancer, with strong histotype-specific effects evident from stronger causal effects for endometrioid and clear cell carcinoma histotypes ( Yarmolinsky  et al. , 2019 ;  Mortlock  et al. , 2022 ). For example, risk variants at the  SKAP1  locus were shared between endometriosis and most histotypes, whereas genomic regions near  KDR ,  GDAP1 , and  VEZT  were specific to clear cell ovarian cancer ( Mortlock  et al. , 2022 ). Discovery of endometriosis-subtype specific genetic variants may reveal further insights into the factors that promote and inhibit malignant transformation.\nRecent MR studies identified an effect of lower testosterone levels on endometriosis risk ( McGrath  et al. , 2023b ;  Zhao  et al. , 2023 ). Support for this influence of lower testosterone on endometriosis comes from evidence of association between endometriosis and shorter anogenital distances, a condition indicative of lower prenatal testosterone concentrations ( Crespi and Dinsdale, 2024 ). Androgens are synthesized in the ovary and adrenal glands, control key functional processes in the endometrium including regulation of endometrial repair and proliferation when circulating oestrogens and progesterone are low ( Simitsidellis  et al. , 2018 ). Relative deficiency of androgens may affect endometriosis risk early in development and/or during reproductive life. Interestingly, low testosterone also appears to be causal for some histotypes of epithelial ovarian cancer, including clear-cell ovarian cancer ( McGrath  et al. , 2023b ). This discovery opens a new research avenue to determine the mechanism(s) of low testosterone in promoting endometriosis and transformation to ovarian cancer.\nThere is evidence for causal effects of depression on endometriosis, but not the reverse relationship ( Adewuyi  et al. , 2021 ). Pathway-based functional enrichment analysis identified ‘abnormality gastric mucosa’ as one major overlapping pathway between the two conditions. Gastro-oesophageal reflux disease was subsequently identified as causal for, but not a consequence of, endometriosis, and to be bidirectionally causal with depression ( Adewuyi  et al. , 2021 ). This suggests endometriosis, depression, and gastric mucosa abnormalities are all causally related ( Adewuyi  et al. , 2021 ). A subsequent study demonstrated bidirectional causal relationships between irritable bowel syndrome and endometriosis, with overlapping genes including  MYSM1  (immune functions) and  FN1  (cell proliferation, motility, invasion, and migration) ( Yang  et al. , 2023 ). Recent sex-stratified GWAS have begun to shed light on the biological underpinnings of sex differences in complex disease ( Sacks  et al. , 2018 ). These findings are particularly relevant in the context of emerging evidence that sex-specific effects may influence conditions associated with endometriosis, including depression, potentially offering new insights into the interconnected pathophysiology of these conditions ( Thomas  et al. , 2025 ).\nGenetic risk, quantified through GRS, has been shown to interact with comorbidities, amplifying endometriosis risk ( McGrath  et al. , 2025 ). For example, the presence of uterine fibroids increased endometriosis prevalence more markedly in women with a high GRS for endometriosis, suggesting that co-occurring conditions can modify the genetic predisposition to disease development. Complementary studies have used large-scale electronic health records and clustering techniques to identify distinct patient subgroups based on comorbidity profiles, ranging from anxiety and musculoskeletal disorders to allergies, anaemia, and migraines, highlighting the clinical heterogeneity of endometriosis ( Sarria-Santamera  et al. , 2023 ;  Khan  et al. , 2025 ). By integrating genetic data with clinical comorbidity profiles, we are beginning to unravel the biological mechanisms driving these interactions, knowledge that will inform more precise risk stratification and personalized care strategies tailored to individual disease trajectories.\nApplication of MR in complex disease genetics has increased dramatically in recent years. However, results should always be viewed with caution. Many submissions to journals are of dubious quality in part because of poor understanding of the methods among researchers and reviewers ( Davey Smith  et al. , 2026 ). Valid MR studies depend on explicit assumptions: genetic variants used must be associated with the exposure; there must be no common sources of confounding; and the variants must influence the outcome directly through the exposure and not via alternative pathways ( McGrath  et al. , 2023c ;  Davey Smith  et al. , 2026 ). A common source of confounding is that genetic factors influence both an exposure and the outcome, and for many published studies, the notion that there are specific genetic influences on the exposures reported is simply implausible ( Davey Smith  et al. , 2026 ). Another important consideration is whether the eﬀect of the genetic variants on the disease of interest matches the eﬀect seen if the same exposure diﬀerence were produced through specific environmental changes. This is a fundamental principal of MR studies and known as gene-environment equivalence ( Davey Smith  et al. , 2026 ). Further research will be needed to determine the validity of each causal relationship and better understand the underlying mechanisms to provide the evidence base for better policy and improve clinical practice.\n\nHigh priorities for research in endometriosis identified by patients and their families, clinicians, researchers, and in National Priority Statements ( Horne  et al. , 2017 ;  Commonwealth of Australia, 2018 ;  Giese  et al. , 2023 ;  Ellis and Wood, 2024 ) include understanding the causes of and risk factors for endometriosis and related issues of pain and infertility, improving diagnosis and treatments, and finding a ‘cure’. Results from genetic studies over the last 25 years address these priorities by discovering the genetic risk factors for endometriosis. Outcomes include mapping 80 genomic regions contributing to genetic risk, identifying candidate genes and pathways potentially involved in disease initiation and progression, elucidating the structure of genetic variation underlying the disease, discovering different genetic risk profiles for minimal/mild and severe disease, and demonstrating genetic overlap and potential causal relationships with comorbid conditions ( Fig. 4 ).\nGenetic contributions to understanding endometriosis risk . Summary of the multiple outcomes from genetic studies of endometriosis risk. Abbreviations; genetic correlation ( r g ), Mendelian Randomisation (MR), genetic risk score (GRS). Created in BioRender. Montgomery, G. (2026).  https://BioRender.com/bzqaf5p .\nFuture studies should address critical questions to enable more rapid translation and personalized treatments. One important question is the causes of disease heterogeneity and possible disease subtypes. The heterogeneity of endometriosis impacts diagnosis, clinical practice and the validity of much published research ( Giudice  et al. , 2023 ). Understanding whether disease subtypes exist is a complex question. Different types of lesions (e.g. superficial peritoneal, deep infiltrating endometriosis, or endometrioma) may represent subtypes, or there could be sub-types within lesion classes defined by specific molecular characteristics. Deep infiltrating endometriosis could result from progression of superficial peritoneal lesions or be a distinct entity. Endometriosis running in families (or associated with a high genetic burden) may be different from sporadic endometriosis (or endometriosis with low genetic burden). Multiple subtypes could coexist in one individual and could be dynamic, evolving from one to another as the disease progresses. Genetic differences associated with disease severity and lesion type support a case for distinct subtypes ( Painter  et al. , 2011 ;  Sapkota  et al. , 2015 ,  2017 ;  Rahmioglu  et al. , 2023 ). As noted earlier, future studies should include a greater proportion of participants with detailed clinical and phenotype data to better understand questions of heterogeneity as advocated for psychiatric disorders ( Agrawal  et al. , 2025 ). While the question of distinct subtypes is being settled, it is also critical that studies employ more robust designs that explicitly define their case samples or are large enough to adequately address the heterogeneity within patient groups and better account of the variation in this disease.\nProgress towards understanding endometriosis pathobiology, as well as improving clinical management, would benefit from more effective integration of genetic evidence. The small fraction of variance in endometriosis risk explained by known genetic variants, together with the limited functional evidence linking these risk variants to disease mechanisms has led to questions about the utility of genetic research for this disease ( Marquardt  et al. , 2023 ; Endometriosis Initiative, 2024). However, genetic variation makes a substantial contribution to individual differences in endometriosis susceptibility. Mapped genetic risk factors point to multiple genes from the hypothalamic-pituitary-gonadal axis which remains the principal target for most drugs used in clinical treatment. Other risk regions likely implicate important pathways and the magnitude of genetic effect sizes for common diseases is not a reliable predictor of the therapeutic relevance of the pathways they implicate ( Duncan and Deisseroth, 2024 ;  Montgomery, 2024 ). Defining how genetic variants contribute to disease risk requires a multidisciplinary approach to prioritize the most promising candidates and employs a range of experimental approaches ( Tapmeier  et al. , 2021 ). Greater emphasis on genetically informed functional studies to identify causal genes, and molecular pathways will help elucidate disease mechanisms. Collecting genetic data together with clinical data and advanced imaging will also help understand the relationship between genetic risk, disease severity, and disease subtypes defined by different classification systems, and can exploit new opportunities from advanced imaging to track disease progression and evaluate genetic risk.\nFunctional genomic datasets are becoming available but remain incomplete, mainly derived from blood or post-mortem samples and often lack genetic data ( Zeng and Visscher, 2025 ). Well powered studies with clinical data, genetic data, gene expression, epigenetics, single cell sequencing, spatial transcriptomics and proteomics across a range of cell types relevant to endometriosis and across diverse experimental and disease conditions will be required to define which risk variants have functional impact ( Zeng and Visscher, 2025 ;  Wray  et al. , 2026 ). Spatial transcriptomics is beginning to show differences in function for the same cell-types in difference locations ( Wray  et al. , 2026 ) and integration of GWAS results with spatial transcriptomic data (gsMap) provides a large library of spatial transcriptomic images annotated with GWAS results for 110 complex traits ( Song  et al. , 2025 ;  Wray  et al. , 2026 ). International genetics studies have demonstrated the value of large collaborative efforts to combine data. Similar collaborative frameworks will benefit functional studies in endometriosis. Robust experimental designs that address specific research questions while enabling data integration across studies will be critical to establish datasets with sufficient statistical power to detect subtle regulatory effects underlying disease processes.\nEnvironmental exposures also contribute substantially to the risk of endometriosis, so gene–environment interactions are probable, yet have not been investigated. Some genetic variants have detectable regulatory effects only under certain environmental exposures. This is observed for immune cells where variants controlling gene expression and methylation changes in response to glucocorticoid exposure are enriched for disease variants ( Knauer-Arloth  et al. , 2025 ) and 60% of colocalizations between genetic risk variants of immune-mediated disorders and CD4+ T cells were observed exclusively in their activated state ( Soskic  et al. , 2022 ). Despite endometriosis being considered an inflammatory condition, the role of the immune system in endometriosis development and progression is not completely clear, so this may be a relevant avenue to explore. Development of an integrated resource and cell atlas for genetic regulation of the epigenome, transcriptome, and proteome for relevant reproductive tissues and endometriotic lesions under various conditions would support functional studies and future translation.\nFamily history is included together with symptom data in some questionnaires designed to assess the likelihood of endometriosis and reduce time to diagnosis ( Nnoaham  et al. , 2012 ;  Verket  et al. , 2019 ;  Chapron  et al. , 2022 ;  Mishra  et al. , 2026 ). Genetic risk scores also capture genetic risk. These two estimates differ because the GRS is calculated from genetic markers while family history captures genetic risk plus effects of shared environment within the family. It will be important to determine which approach is best or whether both together can improve disease prediction. Studies on disease prediction should evaluate the use of symptom information and functional data in prediction models. Evidence on causal relationships between endometriosis and comorbid conditions should be expanded and evaluated for inclusion in clinical guidelines.\nGenetic risk factors so far identified consist mostly of common variants with modest effect sizes that emphasize the complex nature of the disease. Understanding the role of somatic mutations and the search for rare coding variants are important avenues for future studies. A key focus of future studies in the Psychiatric Genetics Consortium ( Agrawal  et al. , 2025 ) is to examine the role of rare variants. Development of large data sets with whole-genome sequencing will provide greater power to detect the presence of rare variants contributing to endometriosis risk ( Wainschtein  et al. , 2026 ). These variants can directly identify the target genes and possible mechanisms of action that could speed up the process for the development of novel and more specific treatments for endometriosis. It is likely that common variants, rare variants, and somatic mutations combine to increase disease risk ( Anglesio  et al. , 2017 ;  Montgomery  et al. , 2020 ;  Wainschtein  et al. , 2026 ) and understanding all causes of variation will help understand disease biology and heterogeneity.\nGenetic studies also help to establish the relationships between endometriosis and related conditions. As an example, leveraging the large genetic datasets available for psychiatric conditions has demonstrated widespread genetic overlap between related conditions challenging narrow definitions of specific disease diagnosis ( Agrawal  et al. , 2025 ). Results for endometriosis and other reproductive disorders are similar (McGrath  et al. , 2023;  Pujol Gualdo  et al. , 2025 ) and clinical guidelines for endometriosis should consider the higher burden of comorbid conditions and their role in disease development and progression. The shared genetic risk factors for related conditions also provide insights that help explain effects on endometriosis risk and identify shared genetic risk factors.\nFurther, these shared genes and pathways may have pre-existing targeted treatments, which may prove useful in treating endometriosis. Repurposing previously approved drugs is an efficient strategy in drug development ( Oskotsky  et al. , 2024 ;  Koller  et al. , 2026 ) as the time and resources taken to demonstrate the drug is safe are significantly reduced, given that its safety profile has already been established in prior clinical trials. The comorbidities also provide preliminary evidence for subtypes of endometriosis. For example, uterine fibroids are more strongly associated with endometriosis on the ovary than endometriosis on the pelvic peritoneum, whereas infertility shows the opposite association ( McGrath  et al. , 2023c ). As the availability of detailed clinical data grows, such endometriosis subtype-specific associations will become feasible to investigate ( McGrath  et al. , 2023a ;  Pujol Gualdo  et al. , 2025 ).\n\nThe significant contribution of genetic risk factors to the development of endometriosis was first established 25 years ago. Despite a slow start in mapping specific risk factors, progress has accelerated dramatically with developments in technology, international collaborations to combine data and increase power, and access to other large genetic and genomics data resources. The top genetic risk factors have been mapped, and these implicate genes involved in development of the reproductive tract, the hypothalamic/pituitary/ovarian axis, regulation of cell proliferation, and regulation of epithelial cell differentiation. The studies also highlight important causal relationships between endometriosis and comorbid conditions with implications for clinical guidelines, a possible role of testosterone in disease development, and potential new drug targets demonstrating prospects for development of novel treatments.\nIn common with most other complex diseases, effects of individual common genetic risk factors are small. However, small effect sizes are not good predictors of the impact of drugs developed against genetically validated targets. Additive effects of small risk factors affect multiple genes in the same pathways and the fact that many potential risk genes act in multiple pathways may contribute to the effects of these genetic risk factors in disease initiation and progression. Genetic factors altering gene regulation may act in specific cell types and could have effects in different cells and tissues. Increasing access to cell-based models, single cell omics, spatial transcriptomics, and proteomics, together with genetic information and advanced statistical methods for multi-omics data integration will further accelerate progress.\nSome aspects of progress from genetic studies are beginning to be included in clinical guidelines and future studies should address critical questions of heterogeneity and disease subtypes, expand the search for genetic risk factors to non-European populations, evaluate genetic prediction together with symptom data for early diagnosis and/or patient stratification, evaluate the role of rare and structural variants, and analyze large genetic datasets to better understand the causal relationships with comorbid conditions. Greater integration of insights from genetic advances into functional and clinical studies to understand endometriosis development and progression will help to accelerate progress towards earlier diagnosis and better treatments.","source_license":"CC-BY-4.0","license_restricted":false}